232 related articles for article (PubMed ID: 33144466)
1. New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.
Dalla Via V; Halter JP; Gerull S; Arranto C; Tichelli A; Heim D; Passweg JR; Medinger M; Cesana-Nigro N
In Vivo; 2020; 34(6):3545-3549. PubMed ID: 33144466
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
4. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
5. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
[TBL] [Abstract][Full Text] [Related]
6. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study.
Valkova V; Jircikova J; Trnkova M; Steinerova K; Keslova P; Lanska M; Koristek Z; Raida L; Krejci M; Kruntoradova K; Dolezal T; Benesova K; Cetkovsky P; Trneny M
Neoplasma; 2016; 63(5):743-51. PubMed ID: 27468878
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
8. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
Fuji S; Rovó A; Ohashi K; Griffith M; Einsele H; Kapp M; Mohty M; Majhail NS; Engelhardt BG; Tichelli A; Savani BN
Bone Marrow Transplant; 2016 Aug; 51(8):1041-9. PubMed ID: 27042848
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
[TBL] [Abstract][Full Text] [Related]
10. [Cytomegalovirus infection monitoring in patients with long-term survival after allogeneic hematopoietic stem cell transplantation].
Chen L; Luo Y; Hu Y; Tan Y; Zhao Y; Fan J; Huang H
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3145-9. PubMed ID: 25573309
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
13. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Medinger M; Zeiter D; Heim D; Halter J; Gerull S; Tichelli A; Passweg J; Nigro N
Leuk Res; 2017 Jul; 58():43-47. PubMed ID: 28433882
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
Aljurf M; Nassar A; Hamidieh AA; Elhaddad A; Hamladji RM; Bazarbachi A; Ibrahim A; Ben Othman T; Abdel-Rahman F; Alseraihy A; Fahmy O; Hussein AA; Alabdulaaly A; Adil S; Alkindi SS; Bayoumy M; Dennison D; Bekadja MA; Redhouane AN; Rasheed W; AlSagheir A; Alsudairy R; Ladeb S; Benchekroun S; Ramzi M; Ahmed P; ElSolh H; Ahmed SO; Hussain F; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):167-75. PubMed ID: 26452331
[TBL] [Abstract][Full Text] [Related]
18. New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.
Engelhardt BG; Savani U; Jung DK; Powers AC; Jagasia M; Chen H; Winnick JJ; Tamboli RA; Crowe JE; Abumrad NN
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1225-1231. PubMed ID: 30738170
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
20. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
